About: ‘’Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece’’

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ‘’Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece’’ Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	‘’Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece’’
Creator	Bakirtzi, K Ioannides, D Lallas, A Papadimitriou, I Sideris, N Sotiriou, E Vakirlis, E Vrani, F
Source	Medline; PMC
abstract	COVID‐19 pandemic raised questions both in dermatologists and in patients about the use of immunosuppressive medications. Although dermatologic societies recommend the continuing of psoriatic systemic therapies and biologics, little is known about treatment adherence in psoriatic patients during COVID‐19 outbreak. Medication self‐management may feel burdensome to patients with psoriasis due to the nature of treatments and many of them face additional challenges as they may suffer from comorbidities. Under these already difficult conditions, COVID‐19 disease puts extra pressure on individuals and may undermine adherence. Acknowledging treatment non‐adherence as a consequence of conflicting goals may help to find the reasons for but, most important, solutions to non‐adherence especially during public health crises. The objective of our study was to evaluate the adherence of psoriatic patients in traditional systemic treatment as well as biologics and identify possible influencing factors of drug interruption during COVID‐10 pandemic.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1111/jdv.16759
bibo:pmid	32558015
has license	no-cc
sha1sum (hex)	f4b843c81a4eb46ac4d36b7d0b3d00d65ed30865
schema:url	https://doi.org/10.1111/jdv.16759
resource representing a document's title	‘’Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece’’
has PubMed Central identifier	PMC7323240
has PubMed identifier	32558015
schema:publication	J Eur Acad Dermatol Venereol
resource representing a document's body	covid:f4b843c81a4eb46ac4d36b7d0b3d00d65ed30865#body_text
is schema:about of	named entity 'COVID-19' named entity 'patients' named entity 'Greece' named entity 'tertiary hospital' named entity 'brodalumab' named entity 'non-adherence' named entity 'apremilast' named entity 'biologics' named entity 'pharmacy' named entity 'biologics' named entity 'etanercept' named entity 'systemic agents' named entity 'comorbidities' named entity 'infection' named entity 'adalimumab' named entity 'COVID-19 disease' named entity 'COVID-19 outbreak' named entity 'secukinumab' named entity 'comorbid conditions' named entity 'risk factors' named entity 'comorbidities' named entity 'dermatologic' named entity 'ustekinumab' named entity 'demographic' named entity 'non-adherence' named entity 'safety profile' named entity 'Greece' named entity 'medical treatment' named entity 'comorbidity' named entity 'non-adherence' named entity 'public health' named entity 'systematic reviews' named entity 'e-mail' named entity 'demographic features' named entity 'health issues' named entity 'self-reports' named entity 'comorbidities' named entity 'COVID-19 outbreak' named entity 'correlation' named entity 'infection' named entity 'long-lasting' named entity 'prognosis' named entity 'COVID-19 pandemic' named entity 'Treatment adherence' named entity 'ADHERENCE' named entity 'PATIENTS' named entity 'psoriatic' named entity 'Title' named entity 'tertiary hospital' named entity 'pandemic' named entity 'adherence' named entity 'GREECE' named entity 'HOSPITAL' named entity 'TERTIARY' named entity 'COVID-19 PANDEMIC' named entity 'TITLE' named entity 'REAL-WORLD DATA'
is part of of	‘’Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece’’ COVID‐19 pandemic raised questions both in dermatologists and in patients about the use of immunosuppressive medications. Although dermatologic societies recommend the continuing of psoriatic systemic therapies and biologics, little is known about treatment adherence in psoriatic patients during COVID‐19 outbreak. Medication self‐management may feel burdensome to patients with psoriasis due to the nature of treatments and many of them face additional challenges as they may suffer from comorbidities. Under these already difficult conditions, COVID‐19 disease puts extra pressure on individuals and may undermine adherence. Acknowledging treatment non‐adherence as a consequence of conflicting goals may help to find the reasons for but, most important, solutions to non‐adherence especially during public health crises. The objective of our study was to evaluate the adherence of psoriatic patients in traditional systemic treatment as well as biologics and identify possible influencing factors of drug interruption during COVID‐10 pandemic. covid:f4b843c81a4eb46ac4d36b7d0b3d00d65ed30865#body_text

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software